Skip to search formSkip to main contentSkip to account menu

Tazemetostat

Known as: N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide 
An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

EPZ-6438
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma
The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or… 
2020
2020
FDA Approves Tazemetostat for the Treatment of Epithelioid Sarcoma
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the… 
2018
2018
Abstract 808: Opportunity for therapeutic expansion in mantle cell lymphoma: Tazemetostat combination synergy status in preclinical MCL models
Tazemetostat (EPZ-6438) is a potent, selective, orally bioavailable small molecule inhibitor of EZH2, the enzymatic subunit of… 
2018
2018
The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial.
Tazemetostat has antitumor activity in B-cell non-Hodgkin lymphoma and advanced solid tumors. 
2017
2017
Abstract 5060: Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
The EZH2 inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase 2 clinical trials for the treatment of non… 
2017
2017
Tazemetostat Is Active, Well Tolerated in Rare Epithelioid Sarcoma
The EZH2 inhibitor tazemetostat has shown good activity and is very well tolerated in an analysis of three trials of patients… 
2017
2017
Tazemetostat Active in Rare Pediatric Solid Tumors
Children with relapsed or refractory INI1-deficient malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated… 
2016
2016
Abstract CT031: The effect of food on the pharmacokinetics (pk) of tazemetostat in patients with cancer
Tazemetostat is a selective oral small molecule inhibitor of enhancer of zeste homolog 2 (EZH2). In preclinical evaluations of… 
2016
2016
Abstract 312: Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma
Tazemetostat is a small molecule inhibitor of the histone methyltransferase EZH2 and is currently in phase 2 clinical trials… 
2016
2016
Abstract CT029: The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors
Background: Tazemetostat is a selective oral small molecule inhibitor of enhancer of zeste homolog 2 (EZH2). Results from in…